Viridian Therapeutics Inc (VRDN) reported better-than-expected financial results for the third quarter of fiscal 2025. The company posted an earnings per share (EPS) of $-0.34, surpassing Wall Street's consensus estimate of $-1.10 by $0.76. Additionally, revenue reached $0.1 billion, exceeding the expected $0.0 billion.
The announcement highlights Viridian's ongoing efforts in the biotechnology sector, where it is advancing multiple candidates for the treatment of thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials, THRIVE and THRIVE-2, to evaluate the safety and efficacy of its lead candidate, veligrotug. Furthermore, it is also pursuing two additional Phase 3 trials, REVEAL-1 and REVEAL-2, for VRDN-003.
Viridian will host an earnings conference call to discuss these results and provide further insights into its business performance. Investors are encouraged to review the full earnings release and listen to management commentary for comprehensive context regarding the quarter's performance and future outlook.
As of November 8, 2025, Viridian's market capitalization stands at $2.62 billion, with a trailing twelve-month EPS of $-4.45. Looking ahead, the company anticipates its next earnings report on May 3, 2026, with an estimated EPS of $-1.1705 and revenue expectations of $0.0 billion.